Pharmaxis concludes Brochitol trial
Friday, 13 June, 2008
Pharmaxis (ASX:PXS) has completed a Phase III clinical trial of its Bronchitol inhalant spray for bronchiectasis.
The 12-month trial was an open label extension to an earlier efficacy trial and was designed to determine the adverse event profile of Bronchitol following prolonged use.
Bronchiectasis is an incurable and chronic lung condition which causes excessive mucus to build up in the lungs, making breathing difficult.
Pharmaxis intends to file a marketing application for Bronchitol after the results are published in July.
Quitting smoking increases life expectancy even for seniors
Although the benefits of quitting smoking diminish with age, there are still substantial gains...
Stem cell transplants treat blindness in mini pigs
Scientists have successfully transplanted retinas made from stem cells into blind mini pigs,...
Sugary drinks raise cardiovascular disease risk, but occasional sweets don't
Although higher sugar intake raises your risk of certain cardiovascular diseases, consuming sweet...
